Navigation Links
Sangamo BioSciences Reports Second Quarter 2009 Financial Results
Date:7/29/2009

ensation which totaled $0.8 million in the second quarter of 2009 compared to $0.6 million in the same period in 2008.

Total operating expenses for the second quarter of 2009 were $9.9 million, compared to $10.8 million for the same period in 2008.

Net interest and other income was $0.6 million for the second quarters of both 2009 and 2008.

Six Month Results

For the six months ended June 30, 2009, the consolidated net loss was $11.3 million, or $0.28 per share, compared to a consolidated net loss of $15.4 million, or $0.38 per share, for the six-month period ended June 30, 2008. Revenues were $7.9 million for the first half of 2009, compared to $5.6 million in the same period in 2008. Total operating expenses were $20.1 million for the first half of 2009 and $22.4 million in the first half of 2008. The decrease in operating expenses for 2009 was primarily associated with decreased manufacturing, preclinical and decreased lab supply expenses partially offset by increased clinical trial expenses.

Recent Highlights

  • Presentation of positive Phase 2 ZFP Therapeutic data at ADA 2009. Sangamo announced the presentation of previously unreleased positive Phase 2 clinical data from its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for diabetic neuropathy (DN) at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA). Data from Sangamo's SB-509-601 and SB-509-701A Phase 2 clinical trials demonstrated that SB-509 treatment resulted in statistically significant and clinically relevant improvements in subjects with moderate and severe DN as compared to placebo. The data have enabled the definition of a responder population for SB-509 for future clinical trials.
  • Achievement of key milestone in cell engineering agreement with Genentech. A key research milestone was achieved in Sangamo's Research a
    '/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
2. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
3. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
4. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
5. Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
6. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
7. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
8. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
9. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
10. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
11. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Research and Markets has announced the ... report to their offering. ... the genetic material or genomes of an organism. It ... discovery and development of diagnostic and therapeutic solutions for ... is supported by three major product segments: Instruments, Consumables, ...
(Date:7/31/2014)... San Francisco, Calif. (PRWEB) July 31, 2014 ... provides newly diagnosed patients with an overview of the ... the management of drug side effects, as well as ... , “We’re grateful to Dr. Sandy Srinivas for organizing ... 25-year survivor of kidney cancer. “Sandy and her colleagues ...
(Date:7/31/2014)... , July 31, 2014   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... quarter 2014 financial results will be released on Thursday, ... a conference call and live webcast at 4:30 p.m. ...
(Date:7/30/2014)... Calif. , July 30, 2014 ... a biopharmaceutical company leading the discovery and development of ... report financial results and highlights for the quarter ended ... the U.S. financial markets close. Regulus ... August 6, 2014, at 5:00 pm Eastern Daylight Time ...
Breaking Biology Technology:Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3
... the promotions of Linda Arterburn, PhD, Francisco Leon, MD, ... "We are pleased,to announce the promotions of several of ... a fine group of talented people working here to ... with celiac,disease, asthma, eye disorders, and other areas to ...
... Business Update to Investors, WILMINGTON, Del., Oct. ... Vice President & General Manager John Ranieri,said the ... programs to,market are on track and making significant ... conversion of cellulosic feedstocks,economically into biofuels., "Biobutanol ...
... OF PHASE II DATA FOR LEAD DRUG CANDIDATE ... Oct. 2 Transave, Inc., a,biopharmaceutical company focused ... of serious lung diseases,today announced that it has ... and Compass Horizon Funding Company LLC, an affiliate ...
Cached Biology Technology:Alba Therapeutics Corporation Announces Promotions 2Alba Therapeutics Corporation Announces Promotions 3Alba Therapeutics Corporation Announces Promotions 4DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 3Transave, Inc. Secures $12.5 Million in New Financing 2Transave, Inc. Secures $12.5 Million in New Financing 3Transave, Inc. Secures $12.5 Million in New Financing 4Transave, Inc. Secures $12.5 Million in New Financing 5
(Date:7/31/2014)... the brain processes speech, potentially increasing the difficulty ... The University of Texas at Dallas. , In ... and Hearing , researchers demonstrated for the first ... recognition of speech sounds. , Noise-induced hearing loss ... an estimated 15 percent of Americans between the ...
(Date:7/31/2014)... identify and treat those with fibromuscular dysplasia (FMD). FMD ... arteries in the body, which can restrict blood flow to ... report appearing in August 2014 issue of The ... may not be limited to the arteries as currently believed. ... and joints, as well as evidence that inflammation may be ...
(Date:7/31/2014)... the Rim Fire was in full fury, raging swiftly ... entered the backcountry of Yosemite National Park in California,s ... park, the battle began to turn, enacting a case ... combine to fuel large, severe fires. , "When the ... where fire had been used as a management tool, ...
Breaking Biology News(10 mins):UT Dallas study reveals effect of loud noises on brain 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5
... will present the 2013 William Dameshek Prize to Andrew S. ... research on the cellular and molecular causes of blood clots. ... MD, a renowned hematologist, past president of ASH, and the ... an individual who has made a recent, outstanding contribution to ...
... known as important sources of energy for all organisms. ... certain types of sugars, known as polysaccharides, may also control ... produce hard structures such as shells and exoskeletons of mollusks, ... of the National Academy of Sciences , Anthony Giuffre, a ...
... is killing you, you may be right, but what you ... even before you were born. In a new report appearing ... Journal , Harvard researchers find that epigenetic disruptions, which ... common at birth. Possibly, these aberrations result from stressors in ...
Cached Biology News:The American Society of Hematology honors Andrew S. Weyrich, Ph.D., with 2013 William Dameshek Prize 2Geoscientists unearth mineral-making secrets potentially useful for new technologies 2Geoscientists unearth mineral-making secrets potentially useful for new technologies 3Fetal stress disrupts the way genes are transmitted 2
Rabbit polyclonal to MAL ( Abpromise for all tested applications). entrezGeneID: 4118 SwissProtID: P21145...
Anti-ADAM-12 (Meltrin Alpha); amino terminal region; rabbit host...
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Biology Products: